Tag:
Cell Therapeutics
Latest Headlines
Latest Headlines
UPDATED: Cell Therapeutics lands myelofibrosis drug with $30M upfront
In addition to the $30 million upfront for the Singapore-based biotech, CEO Jim Bianco committed the company to an unspecified set of milestones for the treatment.
Cell Therapeutics calls retreat on bloodied pixantrone app
Two years after Cell Therapeutics ( $CTIC ) took one of the worst regulatory beatings of the decade at the time the FDA and its experts rejected the company's cancer drug pixantrone , the Seattle-based
Battered Cell Therapeutics pays $5M to in-license AML drug
Bruised and battered by its setback on pixantrone, Cell Therapeutics ( $CTIC ) is adding a new drug to its pipeline, paying $5 million upfront to license the North, Central and South American rights to
Cell Therapeutics raises $25M
Cell Therapeutics has raised $25 million by granting preferred stock and warrants to a single unnamed institutional investor. In a statement, the company says it intends to use the net proceeds from
Cell Therapeutics ($CTIC) appeals FDA decision on pixantrone
Cell Therapeutics said today that, as planned , it's submitted a formal appeal to the FDA regarding the agency's decision to reject pixantrone, an experimental treatment for relapsed/refractory
NASDAQ gives Cell Therapeutics ($CTIC) another warning
NASDAQ is giving Cell Therapeutics ( $CTIC ) another 180 days to regain compliance with Nasdaq's $1.00 minimum bid price rule. This is Cell Therapeutics second warning; In early May, Nasdaq notified
Cell Therapeutics gets OK to sell more shares
With its options running out, the financially strapped Cell Therapeutics ( CTIC ) has won shareholder approval for a plan to sell another 400,000 shares to keep the biotech afloat for now. Without
CTI will appeal FDA pixantrone ruling
Cell Therapeutics doesn't want to take 'no' for an answer. The developer, which recieved a harsh FDA rejection of pixantrone for relapsed/refractory aggressive non-Hodgkin's lymphoma, said today that
Which biotechs are the least efficient?
SmartTrend has looked at the biotech industry to determine which companies are the least efficient. Using revenue per employee (RPE)--a ratio useful when comparing a company against others in its
Struggling Cell Therapeutics raises $21M in stock sale
Just weeks after the FDA's embarrassing rejection of its cancer drug pixantrone , Seattle-based Cell Therapeutics ( CTIC ) said it was able to raise $21 million through the sale of preferred stock to
